INTRODUCTION AND OBJECTIVES
Concern regarding coexisting malignant pathology in benign renal tumors deters renal biopsy and questions its validity. We examined rates of coexisting malignant and high grade pathology in resected benign solid solitary renal tumors.
METHODS
Using our prospectively maintained database we identified patients with solitary solid renal tumors who underwent surgical resection between 1994 and 2012 (n=1829). Lesions containing elements of renal oncocytoma (RO), angiomyolipoma (AML) or other benign pathology formed the basis for this analysis. Patients having an oncocytic malignancy, without presence of a classic oncocytoma, and those with known hereditary syndromes were excluded.
RESULTS
147 patients with pathologically proven elements of RO (n=96), AML (n=44), and other solid benign pathology (n=7) were identified. Median tumor size was 3.0 cm (IQR 2.2 – 4.5) and tumor anatomic complexity, as quantified by the RENAL NS, was low in 28%, moderate in 56%, and high in 16%. Only 4 patients (2.7%) were documented as having hybrid malignant pathology, all involving low grade chromophobe RCC in the setting of RO. After a median follow-up of 44 (IQR 33 – 55) months, no patients with hybrid tumors experienced regional or metastatic progression.
CONCLUSIONS
In our cohort of patients with a solitary, sporadic, solid benign renal mass, <3% of tumors exhibited coexisting hybrid malignancy. Importantly, no patients harbored coexisting high grade pathology. These data suggest that uncertainty regarding hybrid malignant pathology coexisting with benign pathologic components should not deter renal biopsy, especially in the elderly and comorbid.